Home / Diagnostic Services / Publications & Resources /

Posters

Posters

Diagnostic Services Resources

<img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/02/national-cancer-institute-LnvCEXQwC-o-unsplash-scaled-1.jpg"/>

Impact of DNA Repair Deficiency Signature on Outcomes in Triple Negative Breast Cancer (TNBC) Patients Treated with AC Chemotherapy

<img decoding="async" class="c-knowledge-module--img lazyload" data-src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/06/shutterstock_659631763_.jpg" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/06/shutterstock_659631763_.jpg"/>

Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma

<img decoding="async" class="c-knowledge-module--img lazyload" data-src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/06/shutterstock_659631763_.jpg" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/06/shutterstock_659631763_.jpg"/>

Poster Predictive assay for anti-angiogenic agents identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab

<img decoding="async" class="c-knowledge-module--img lazyload" data-src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/06/shutterstock_659631763_.jpg" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/06/shutterstock_659631763_.jpg"/>

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

<img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/02/national-cancer-institute-L7en7Lb-Ovc-unsplash-scaled-1.jpg"/>

Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response

A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localised prostate cancer treated with primary radical treatment

<img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/02/national-cancer-institute-LnvCEXQwC-o-unsplash-scaled-1.jpg"/>

Platinum-based therapy selects for an angiogenic enriched tumour micro-environment in High Grade Serous Ovarian Cancer

Almac Diagnostic Services GU-ASCO Poster

Identification of a high-risk subgroup in primary prostate cancers presenting with targetable immune biology

The development and utilisation of a novel DNA microarray platform for biomarker and target identification in advanced prostate cancer

Development of Expression Based Biomarkers in NSCLC: A Study of Intratumor Heterogeneity Using FFPE Tissue

DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

<img decoding="async" class="c-knowledge-module--img" src="https://www.almacgroup.com/knowledge/wp-content/uploads/sites/10/2021/02/national-cancer-institute-L7en7Lb-Ovc-unsplash-scaled-1.jpg"/>

DNA Damage Response Deficiency (DDRD) in Breast Cancer is associated with a STING-dependent Innate Immune Response

A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localised prostate cancer treated with primary radical treatment

Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma

Impact of DNA Repair Deficiency Signature on Outcomes in Triple Negative Breast Cancer TNBC Patients Treated with AC Chemotherapy

Platinum-based therapy selects for an angiogenic enriched tumour micro-environment in High Grade Serous Ovarian Cancer

Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signalling

Predictive assay for anti-angiogenic agents (AADx) identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab – analysis of the FIRE-3 (AIO KRK-0306) trial

Stay up-to-date with Almac Diagnostic Services

Join our mailing list

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies